GLPwatch
Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
Lancet Diabetes Endocrinol · 2026
Last updated 2026-07-22| Journal | Lancet Diabetes Endocrinol, 2026 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide, cagrilintide |
Full record and abstract on PubMed 42251858 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.